Physician profile
Karin Fuller
NPI 1225743495
$5,704.50
in general payments reported to CMS, 2019-2025
24 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,339 · 2024: $1,844 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,468 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,467.56 |
| Education | $236.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,046.13 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $909.86 | 2023-2025 | |
| Ucb, INC. | $487.86 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $455.03 | 2023-2024 | Tremfya |
| Genzyme Corporation | $437.86 | 2023-2025 | |
| Amgen INC. | $399.19 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $331.49 | 2023-2025 | |
| Lilly USA, LLC | $236.67 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $224.12 | 2024-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $191.65 | 2023-2024 | Vtama |
| Leo Pharma INC. | $181.26 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $165.88 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $154.91 | 2023-2025 | Odomzo, Blu-U |
| Arcutis Biotherapeutics, INC. | $122.22 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $46.34 | 2023-2024 | Ycanth |
| Organon LLC | $44.46 | 2024-2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $41.31 | 2023-2025 | Valchlor |
| Incyte Corporation | $40.56 | 2023 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.09 | 2024 | Spevigo |
| Kerecis Limited | $22.87 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Kyowa Kirin, INC. | $18.86 | 2025 | |
| Botanix Sb INC | $17.55 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $14.38 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.